Physician profile
Thomas A Ginn
NPI 1770506511
$7,307.78
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,447 · 2020: $1,909 · 2021: $2,711 · 2022: $1,241.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,413.98 | 2019-2022 | |
| Abbvie INC. | $632.13 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $619.32 | 2019-2021 | |
| Pfizer INC. | $588.48 | 2019-2022 | |
| Astellas Pharma US INC | $393.09 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $391.57 | 2019-2022 | |
| Amarin Pharma, INC. | $339.89 | 2019-2022 | |
| Lilly USA, LLC | $334.76 | 2020-2022 | |
| Amgen INC. | $252.89 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $247.36 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $218.84 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $201.34 | 2019-2022 | |
| Esperion Therapeutics, INC. | $199.85 | 2021 | |
| Janssen Pharmaceuticals, INC | $186.25 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $151.07 | 2019-2022 |
Show all 41 companies
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Ginn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.